Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sacituzumab tirumotecan (SKB264) plus SKB118 in EGFR-mutant non-squamous NSCLC after EGFR-TKI failure
CTR20263752Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, CR-001 in non-small cell lung cancer (NSCLC), sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Oct 2026; status: active.
02
Drugs
sacituzumab tirumotecanCR-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263752.